Welcome! Our laboratory studies the mechanisms underlying complex neurodegenerative diseases, including Alzheimer’s Disease, Parkinson’s Disease and Frontotemporal Lobar Degeneration (FTLD). Our techniques range from cellular neurobiology to population studies and clinical trials. We’re interested in identifying new disease-related biological pathways, evaluating new experimental therapeutics, and developing new disease-specific biomarkers.
News
May 04, 2026 - Wilson Lab Contributes to Blood and CSF Biomarker Best-Practice GuidelinesWe are excited to share that our lab contributed to the new “Pre-analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices Workgroup,” now published in Alzheimer’s & Dementia. These guidelines, updated for the first time since 2014, reflect current ADRC best practices to minimize pre-analytical variability in blood and CSF biomarker studies and to harmonize protocols across centers. Click here to read the paper.
Apr 02, 2026 - Welcome, Nola!We are thrilled to welcome Nola Ihejirika to the lab! Nola is a Doctoral Student in Brown University's Pathobiology Program.
Nola will be working on synaptic resilience in Alzheimer's disease.
Welcome, Nola!
Dec 06, 2025 - Ted Wilson appointed to named chairTed Wilson named Provost’s Assistant Professor of Neuroimmunology and Brain Science.
Dec 01, 2025 - We’ve moved!The Wilson Lab has moved to Brown University! Contact us if you are interested in collaborating or joining our group of exceptional scientists!
Sep 03, 2025 - Ted and Bella were recently featured in Stanford’s Neuroscience NewsStanford undergrads and local community college students paired with Wu Tsai Neurosciences Institute researchers to find new ways to head off strokes, predict Alzheimer's disease, and more.
Latest Publications
Van Meter TE, Wilson EN, Elahi F, Rissman RA, Lago AL, Faber K, Gauthreaux K, Osorio R, Perkins M, Gray N, Morris J, Liu A, Stockwell H, Kukull W, Wilson R, Wingo TS, Kanaan NM, Russ K, Wilcock D, Biber SA, Bekris LM, Karikari TK. Pre-analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices Workgroup. Alzheimers Dement. 2026 May;22(5):e71252. doi: 10.1002/alz.71252. PMID: 42080228; PMCID: PMC13137281. [PubMed]
Bettcher BM, Ren S, Wang Y, Carlson NE, Lippitt WL, McConnell BV, Wilson EN, Shapiro ALB, Coughlan C, Carlisle TC, Unger JR, Cook GG, Bengtson K, Gorla L, Ueberheide BM, Kanshin E, Potter H, Schulz L, Frazer-Abel A, Pelak VS. Relation of blood-based inflammation conditional networks to key immune health status and Alzheimer's biomarkers in aging adults. Neurobiol Aging. 2026 May 9;166:14-28. doi: 10.1016/j.neurobiolaging.2026.05.001. Epub ahead of print. PMID: 42139770. [PubMed]
Winer JR, Plastini MJ, Romero A, Vossler H, Sai I, Channappa D, Abdelnour C, Shahid-Besanti M, Wilson EN, Oh HS, Young CB, Trelle A, Yutsis M, Sha SJ, Ramirez V, Taylor R, Younes K, Wyss-Coray T, Greicius MD, Henderson VW, Wagner AD, Poston KL, Mormino EC. Effects of α-synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging. Alzheimers Dement. 2026 May;22(5):e71455. doi: 10.1002/alz.71455. PMID: 42071168; PMCID: PMC13135916. [PubMed]
Trelle AN, Cody KA, Nguyen TT, Winer JR, Weiss S, Sai I, Ward T, Cheng G, Channappa D, Mendiola J, Al-Rajhi A, Raghuraman K, Sha SJ, Wilson EN, Wyss-Coray T, Maecker HT, Wagner AD, Mormino EC. Plasma proteomic signatures of preclinical Alzheimer's disease in clinically unimpaired older adults. Mol Neurodegener. 2026 Apr 24. doi: 10.1186/s13024-026-00941-5. Epub ahead of print. PMID: 42032756. [PubMed]
